24/7 Pet Web Search

Search results

1. Results From The WOW.Com Content Network

2. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [6] [7] [8] Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of ...

3. Medicare now negotiating price of drug that costs $7,100 in ...

   www.aol.com/medicare-now-negotiating-price-drug...

   The annual list price of Bristol Myers Squibb’s Eliquis, a blood thinner that reduces the risk of stroke, is $7,100 in the US. But in Japan, it’s $940; in Canada, it’s $900; in Germany, it ...

4. Subanalysis of Phase III ARISTOTLE Trial of Eliquis ... - AOL

   www.aol.com/news/2013-09-03-subanalysis-of-phase...

   Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart ...

5. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Medical use. Direct factor Xa inhibitors include rivaroxaban, apixaban and edoxaban, and are types of direct oral anticoagulant (DOAC), which are blood thinning drugs, one of the classes of antithrombotic drugs. [4] [5] [6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non ...

6. New Eliquis® (apixaban) Post-hoc Subanalysis of the ... - AOL

   www.aol.com/2013/08/31/new-eliquis-apixaban-post...

   New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon Results ...

7. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Discovery and development of direct Xa inhibitors. Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States ...